<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;p&gt;Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting&lt;br /&gt;AGENCY: Food and Drug Administration, HHS.&lt;br /&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;This notice announces a forthcoming meeting of a public advisory committee&lt;br /&gt;of the Food and Drug Administration (FDA). The meeting will be open to the&lt;br /&gt;public.&lt;/p&gt;&lt;p&gt;&lt;br /&gt;Name of Committee: Anesthesiology and Respiratory Therapy Devices Panel&lt;br /&gt;of the Medical Devices Advisory Committee.&lt;/p&gt;&lt;p&gt;&lt;br /&gt;General Function of the Committee:&lt;br /&gt;To provide advice and recommendations to the agency on&lt;br /&gt;FDA&amp;rsquo;s regulatory issues.&lt;/p&gt;&lt;p&gt;&lt;br /&gt;Date and Time: The meeting will be&lt;br /&gt;held on October 28, 2009, from 8 a.m. to 5 p.m.&lt;/p&gt;&lt;p&gt;&lt;br /&gt;Location: Hilton Washington DC&lt;br /&gt;North/Gaithersburg, Salons A, B, &amp;amp; C,&lt;br /&gt;620 Perry Pkwy., Gaithersburg, MD.&lt;/p&gt;&lt;p&gt;&lt;br /&gt;Contact Person: Neel J. Patel, Center for Devices and Radiological Health&lt;br /&gt;(Bldg. 66, rm. 2532), Food and Drug Administration, 10903 New Hampshire&lt;br /&gt;Ave., Silver Spring, MD 20993&amp;ndash;0002,&lt;/p&gt;&lt;p&gt;301&amp;ndash;796&amp;ndash;5580, or FDA Advisory&lt;br /&gt;Committee Information Line, 1&amp;ndash;800&amp;ndash;741&amp;ndash;8138 (301&amp;ndash;443&amp;ndash;0572 in the&lt;br /&gt;Washington, DC area), code 3014512624. Please call the Information&lt;br /&gt;Line for up-to-date information on this meeting. A notice in the Federal&lt;br /&gt;Register about last minute modifications that impact a previously announced&lt;br /&gt;advisory committee meeting cannot always be published quickly enough to&lt;br /&gt;provide timely notice. Therefore, you should always check the agency&amp;rsquo;s Web&lt;br /&gt;site and call the appropriate advisory committee hot line/phone line to learn&lt;br /&gt;about possible modifications before coming to the meeting.&lt;br /&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;Agenda: On October 28, 2009, the committee will discuss, make&lt;br /&gt;recommendations, and vote on a premarket approval application for the&lt;br /&gt;Alair Bronchial Thermoplasty System sponsored by Asthmatx, Inc. The device&lt;br /&gt;is indicated for the treatment of severe persistent asthma in adults.&lt;br /&gt;FDA intends to make background material available to the public no later&lt;br /&gt;than 2 business days before the meeting.&lt;/p&gt;&lt;p&gt;&lt;br /&gt;If FDA is unable to post the background material on its Web site prior to the&lt;br /&gt;meeting, the background material will be made publicly available at the&lt;br /&gt;location of the advisory committee meeting, and the background material&lt;br /&gt;will be posted on FDA&amp;rsquo;s Web site after the meeting. Background material is&lt;br /&gt;available on the FDA Internet under the appropriate date at http://www.fda.gov/&lt;br /&gt;AdvisoryCommittees/Calendar/default.htm. Scroll down to the&lt;br /&gt;appropriate advisory committee link.&lt;/p&gt;&lt;p&gt;&lt;br /&gt;Procedure: Interested persons may present data, information, or views,&lt;br /&gt;orally or in writing, on issues pending before the committee. Written&lt;br /&gt;submissions may be made to the contact person on or before October 22, 2009.&lt;br /&gt;Oral presentations from the public will be scheduled between approximately 1&lt;br /&gt;p.m. and 2 p.m. Those desiring to make formal oral presentations should notify&lt;br /&gt;the contact person and submit a brief statement of the general nature of the&lt;br /&gt;evidence or arguments they wish to present, the names and addresses of&lt;br /&gt;proposed participants, and an indication of the approximate time&lt;br /&gt;requested to make their presentation on or before October 15, 2009. Time&lt;br /&gt;allotted for each presentation may be limited. If the number of registrants&lt;br /&gt;requesting to speak is greater than can be reasonably accommodated during the&lt;br /&gt;scheduled open public hearing session, FDA may conduct a lottery to determine&lt;br /&gt;the speakers for the scheduled open public hearing session. The contact&lt;br /&gt;person will notify interested persons regarding their request to speak by&lt;br /&gt;October 16, 2009.&lt;/p&gt;&lt;p&gt;&lt;br /&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the&lt;br /&gt;agency is not responsible for providing access to electrical outlets.&lt;br /&gt;FDA welcomes the attendance of the public at its advisory committee&lt;br /&gt;meetings and will make every effort to accommodate persons with physical&lt;br /&gt;disabilities or special needs. If you require special accommodations due to&lt;br /&gt;a disability, please contact AnnMarie Williams, Conference Management&lt;br /&gt;Staff, at 301&amp;ndash;796&amp;ndash;5966, at least 7 days in advance of the meeting.&lt;br /&gt;FDA is committed to the orderly conduct of its advisory committee&lt;br /&gt;meetings. Please visit our Web site at http://www.fda.gov/Advisory&lt;br /&gt;Committees/AboutAdvisoryCommittees/ucm111462.htm for procedures on&lt;br /&gt;public conduct during advisory committee meetings.&lt;/p&gt;&lt;p&gt;&lt;br /&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5&lt;br /&gt;U.S.C. app. 2). Dated: September 17, 2009. David Horowitz,&lt;br /&gt;Assistant Commissioner for Policy.&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
